This website is intended for healthcare professionals only.
RWE IN mPaCa - MEANINGFUL COUNTRY PERSPECTIVES
Prof. Teresa Macarulla
MD, PhD Head of the Gastrointestinal
Cancer Program Unit at Vall d’Hebron
University Hospital, Barcelona, Spain
Dr. Akihiro Ohba
MD Physician of Department of
Hepatobiliary and Pancreatic Oncology,
National Cancer Center, Tokyo, Japan
This webinar introduces the latest real-world results in mPaCa in Europe and Asia, which confirms both the efficacy and safety of Nal-IRI + 5-FU/LV as 2L treatment. The real-world data presented also offers insights into how to optimize mPaCa management. An interactive clinical case is presented at the end of the webinar to discuss AE management.
Key points covered
This webinar presents the latest real world data on Nal-IRI+5-FU/LV, confirming its efficacy and safety in mPaCa.
The distinct safety profile of Nal-IRI+5-FU/LV, and therefore AE management needs of Asian patients
The importance of treatment planning in mPaCa
The characteristics of Nal-IRI+ 5-FU/LV long-term responders
The value of dose reductions in AE management
An interactive clinical patient case is also presented, with a focus on AE management and dose reduction.
Webinar Replay
Featured Speakers
Prof. Teresa Macarulla
Teresa Macarulla, MD, PhD, is an active member of the European Society for Medical Oncology and the American Society of Clinical Oncology. She is an ad hoc reviewer for various oncology journals. Furthermore, she actively participates in Phase I, II and III studies with new chemotherapy agents in gastrointestinal tumors. She is specialized in translational research on hepatobiliopancreatic tumors and targeted therapies such as EGFR inhibitors.
Dr. Akihiro Ohba
Dr. Akihiro Ohba graduated from Hamamatsu University, School of Medicine, Shizuoka, Japan. He worked as a junior resident at Hadano Red Cross Hospital, Kanagawa, a senior resident at Keiyu Hospital, Kanagawa, and a fellow at National Cancer Center, Tokyo. He is a medical oncologist who specializes in hepatobiliary and pancreatic cancer and a delegate of the hepatobiliary and pancreatic oncology group in the Japan Clinical Oncology Group.
